^
No biomarker
Fibrosarcoma
imatinib
Sensitive
:
A1
No biomarker
Fibrosarcoma
pembrolizumab
Sensitive
:
A2
NTRK1 fusion
Neurofibrosarcoma
entrectinib
Sensitive
:
C1
NTRK3 fusion
Neurofibrosarcoma
entrectinib
Sensitive
:
C1
BRAF V600E
Neurofibrosarcoma
vemurafenib
Sensitive
:
C1
NTRK3 fusion
Fibrosarcoma
larotrectinib
Sensitive
:
C1
NTRK2 fusion
Fibrosarcoma
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Fibrosarcoma
larotrectinib
Sensitive
:
C1
NF2 E108X
Neurofibrosarcoma
everolimus
Resistant
:
C3
NF2 E108X
Neurofibrosarcoma
temsirolimus
Sensitive
:
C3
TSC2 A736V
Neurofibrosarcoma
everolimus
Resistant
:
C3
TSC2 A736V
Neurofibrosarcoma
temsirolimus
Sensitive
:
C3
SQSTM1-NTRK1 fusion
Fibrosarcoma
VAC
Resistant
:
C4
ETV6-NTRK3 fusion
Fibrosarcoma
VAC
Resistant
:
C4
RBPMS-MET fusion
Fibrosarcoma
cabozantinib tablet
Sensitive
:
C4
SQSTM1-NTRK1 fusion
Fibrosarcoma
doxorubicin hydrochloride + ifosfamide
Resistant
:
C4
ETV6-NTRK3 fusion
Fibrosarcoma
larotrectinib
Sensitive
:
C4
ETV6-NTRK3 fusion
Fibrosarcoma
vincristine + dactinomycin
Resistant
:
C4
TMB-H + PD-L1 overexpression
Fibrosarcoma
cisplatin + ifosfamide + epirubicin
Resistant
:
C4
TMB-H + PD-L1 overexpression
Fibrosarcoma
camrelizumab
Sensitive
:
C4
TMB-H + PD-L1 overexpression
Fibrosarcoma
anlotinib
Resistant
:
C4
TFG-ROS1 rearrangement
Fibrosarcoma
crizotinib
Sensitive
:
C4
TJP1-ROS1 fusion + NF1 mutation
Neurofibrosarcoma
crizotinib
Resistant
:
C4
ALK1 rearrangement
Fibrosarcoma
ceritinib
Resistant
:
C4
ALK1 rearrangement
Fibrosarcoma
crizotinib
Resistant
:
C4
CD8 positive
Fibrosarcoma
NKTR-214
Sensitive
:
D
CSPG4 overexpression
Fibrosarcoma
CSPG4.TNK
Sensitive
:
D
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
ceritinib + brentuximab vedotin
Sensitive
:
D
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
crizotinib + brentuximab vedotin
Sensitive
:
D
NF1 mutation
Neurofibrosarcoma
DR6MP + JHU395
Sensitive
:
D
NF1 mutation
Neurofibrosarcoma
DR6MP
Sensitive
:
D
NF1 mutation
Neurofibrosarcoma
MEK inhibitor + c-MET inhibitor
Sensitive
:
D